0001178913-18-003085.txt : 20181204
0001178913-18-003085.hdr.sgml : 20181204
20181204160538
ACCESSION NUMBER: 0001178913-18-003085
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181203
FILED AS OF DATE: 20181204
DATE AS OF CHANGE: 20181204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wiley Matthew T.
CENTRAL INDEX KEY: 0001759703
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36621
FILM NUMBER: 181216868
MAIL ADDRESS:
STREET 1: C/O FOAMIX PHARMACEUTICALS LTD.
STREET 2: 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 7670402
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd.
CENTRAL INDEX KEY: 0001606645
STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
BUSINESS PHONE: 97289316233
MAIL ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
FORMER COMPANY:
FORMER CONFORMED NAME: Foamix Ltd.
DATE OF NAME CHANGE: 20140428
4
1
zk1822341.xml
OWNERSHIP DOCUMENT
X0306
4
2018-12-03
0
0001606645
Foamix Pharmaceuticals Ltd.
FOMX
0001759703
Wiley Matthew T.
C/O FOAMIX PHARMACEUTICALS LTD.
2 HOLTZMAN STREET
REHOVOT
L3
7670402
ISRAEL
0
1
0
0
Chief Commercial Officer
Ordinary Shares
2018-12-03
4
A
0
50000
0.00
A
50000
D
Options
4.06
2018-12-03
4
A
0
100000
0
A
2028-12-03
Ordinary Shares
100000
100000
D
The equity incentive grants were approved by the Issuer's board of directors on the recommendation of a committee of the board on November 14, 2018 with a grant date of December 3, 2018.
The ordinary shares underlying this restricted share unit award vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on December 31, 2019 and 6.25% every three months thereafter) ending December 31, 2022.
This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
Each option represents a contingent right to purchase one ordinary share of the issuer.
The ordinary shares underlying these options vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on December 31, 2019 and 6.25% every three months thereafter) ending December 31, 2022.
/s/ Ilan Hadar as attorney-in-fact for Matthew Wiley
2018-12-04